- Home
- CCEL vs YI Comparison
CCEL vs YI Comparison
Compare CCEL & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- YI
- Stock Information
- Founded
- CCEL 1989
- YI 2010
- Country
- CCEL United States
- YI China
- Employees
- CCEL N/A
- YI N/A
- Industry
- CCEL Managed Health Care
- YI Retail-Drug Stores and Proprietary Stores
- Sector
- CCEL Health Care
- YI Consumer Staples
- Exchange
- CCEL Nasdaq
- YI Nasdaq
- Market Cap
- CCEL 34.8M
- YI 38.1M
- IPO Year
- CCEL 1997
- YI N/A
- Fundamental
- Price
- CCEL $4.20
- YI $4.18
- Analyst Decision
- CCEL Hold
- YI
- Analyst Count
- CCEL 1
- YI 0
- Target Price
- CCEL N/A
- YI N/A
- AVG Volume (30 Days)
- CCEL 5.1K
- YI 8.9K
- Earning Date
- CCEL 10-15-2025
- YI 11-26-2025
- Dividend Yield
- CCEL 15.26%
- YI N/A
- EPS Growth
- CCEL N/A
- YI N/A
- EPS
- CCEL N/A
- YI N/A
- Revenue
- CCEL $31,747,500.00
- YI $1,979,883,442.00
- Revenue This Year
- CCEL $0.30
- YI N/A
- Revenue Next Year
- CCEL N/A
- YI N/A
- P/E Ratio
- CCEL N/A
- YI N/A
- Revenue Growth
- CCEL N/A
- YI N/A
- 52 Week Low
- CCEL $4.09
- YI $3.93
- 52 Week High
- CCEL $9.43
- YI $11.35
- Technical
- Relative Strength Index (RSI)
- CCEL 37.76
- YI 32.66
- Support Level
- CCEL $4.35
- YI $4.20
- Resistance Level
- CCEL $4.54
- YI $4.43
- Average True Range (ATR)
- CCEL 0.13
- YI 0.17
- MACD
- CCEL -0.02
- YI 0.03
- Stochastic Oscillator
- CCEL 0.00
- YI 29.41
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.